FDA Brief

Warning letters Drugs

FDA warning letter to

Evelyn Lopez-Brignoni, M.D.

High riskIssued Mar 2, 2021Posted Mar 9, 2021Center for Drug Evaluation and Research

FDA warns Dr. Evelyn Lopez-Brignoni over inadequate dosing in pediatric investigational drug trials.

What happened

FDA inspected the clinical site from June 8 to June 23, 2020, as part of its Bioresearch Monitoring Program and reviewed the site’s July 7, 2020 response. FDA found that two pediatric protocols required specific study-drug dosing, but subjects received less than the required dose; some may have received placebo only or less than the full intended dose. FDA said this raises concerns about subject safety and the validity and integrity of the data.

What FDA found

  1. The investigator did not ensure the clinical investigations were conducted according to the investigational plan.

    21 CFR 312.60
  2. In the two pediatric studies, subjects did not receive the required study-drug dosing, and some may have received placebo only or less than the full intended dose.

    21 CFR 312.60
  3. FDA said the majority of randomized subjects did not receive sufficient dosing to support the studies’ primary objectives, raising concerns about data validity and integrity.

    21 CFR 312.60

What FDA wants

Within 15 working days of receiving the letter, the investigator should write to FDA describing actions taken to prevent future violations. FDA also asks the investigator to specify the corrective actions taken as clinical investigator, not only site-staff actions.

Who should pay attention

  • clinical research sites running pediatric trials
  • sponsors and CROs monitoring investigator-led studies
  • IRBs and research compliance teams

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  2. Bertrand P. Cole, D.O.

    FDA warns Dr. Bertrand P. Cole that he gave four trial subjects too much drug by not following the study plan.

    High risk
  3. Purushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital

    FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.

    High risk
  4. Devalingam Mahalingam, M.D., Ph.D.

    FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.

    High risk